Medical University of Vienna
Vienna, 1090, Austria
NCT Number: NCT07234318
The FOCUS study aims to evaluate the clinical efficacy of 0.1% cyclosporine eye drops solution (Vevizye®, Laboratoires THEA) in patients with moderate to severe dry eye disease characterized by ocular surface inflammation.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Vienna, 1090, Austria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ophthalmic exclusion criteria
Systemic / non ophthalmic exclusion criteria:
•Known hypersensitivity to any of the components of the medical product under investigation or other study medication
Specific exclusion criteria for women:
Exclusion criteria
related to general conditions
This medicinal product contains cyclosporine 0.1% as an active ingredient and pefluorobutylpentane as vehicle.
Time frame: at week 12 versus baseline
Scores will be determined using a 100 mm VAS on which 0 means "no feeling of eye dryness" and 100 means "most imaginable feeling of eye dryness".
Laboratoires Thea
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07639034
Dry Eye Disease (DED), Dry Eye Syndromes
La Jolla, California, United States
View Trial DetailsNCT07588074
Conjunctival Diseases, Conjunctivitis
Baton Rouge, Louisiana, United States
View Trial DetailsNCT07060131
Dry Eye Disease (DED), Dry Eye Syndromes
Taichung, North Dist, Taiwan
View Trial DetailsNCT07551843
Dry Eye Disease (DED), Dry Eye Syndromes
Athens, Attica, Greece
View Trial Details